A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted by number of followers
Nature Reviews Drug Discovery     Full-text available via subscription   (Followers: 352)
Journal of Clinical Oncology     Hybrid Journal   (Followers: 260)
International Journal of Drug Policy     Hybrid Journal   (Followers: 241)
Journal of Medicinal Chemistry     Hybrid Journal   (Followers: 167)
Drugs     Full-text available via subscription   (Followers: 146)
Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 140)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 95)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 84)
Drug Safety     Full-text available via subscription   (Followers: 81)
Pharmaceutical Research     Hybrid Journal   (Followers: 69)
Drug Discovery Today     Full-text available via subscription   (Followers: 63)
Biomaterials     Hybrid Journal   (Followers: 54)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 52)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 31)
Pharmacoepidemiology and Drug Safety     Hybrid Journal   (Followers: 29)
AAPS Journal     Hybrid Journal   (Followers: 29)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 27)
Journal of Pain & Palliative Care Pharmacotherapy     Hybrid Journal   (Followers: 26)
Regulatory Toxicology and Pharmacology     Hybrid Journal   (Followers: 26)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 25)
Journal of Controlled Release     Hybrid Journal   (Followers: 25)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 25)
International Journal of Pharmacy Practice     Full-text available via subscription   (Followers: 24)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 23)
International Journal of Pharmaceutics     Hybrid Journal   (Followers: 23)
Journal of Clinical Psychopharmacology     Hybrid Journal   (Followers: 23)
Journal of Pharmacy and Pharmacology     Full-text available via subscription   (Followers: 23)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 22)
PharmacoEconomics     Full-text available via subscription   (Followers: 21)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 20)
Chemical Research in Toxicology     Hybrid Journal   (Followers: 20)
Trends in Pharmacological Sciences     Full-text available via subscription   (Followers: 17)
Clinical Toxicology     Hybrid Journal   (Followers: 17)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 16)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Journal of Natural Products     Hybrid Journal   (Followers: 16)
Journal of Pharmacokinetics and Pharmacodynamics     Hybrid Journal   (Followers: 16)
Toxicology and Applied Pharmacology     Hybrid Journal   (Followers: 16)
Pharmaceutical Development and Technology     Hybrid Journal   (Followers: 16)
Journal of Applied Toxicology     Hybrid Journal   (Followers: 15)
Psychopharmacology     Hybrid Journal   (Followers: 15)
Journal of Clinical Pharmacy and Therapeutics     Hybrid Journal   (Followers: 14)
Journal of Oncology Pharmacy Practice     Hybrid Journal   (Followers: 14)
Journal of the American Pharmacists Association     Full-text available via subscription   (Followers: 14)
Toxicology     Hybrid Journal   (Followers: 14)
International Journal of Toxicology     Hybrid Journal   (Followers: 13)
Journal of Pharmaceutical and Biomedical Analysis     Hybrid Journal   (Followers: 13)
Journal of Pharmacy Practice     Hybrid Journal   (Followers: 13)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 12)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 12)
Clinical Trials     Hybrid Journal   (Followers: 12)
Toxicology Letters     Hybrid Journal   (Followers: 12)
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 12)
American Journal of Therapeutics     Hybrid Journal   (Followers: 11)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 11)
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 11)
Journal of Psychopharmacology     Hybrid Journal   (Followers: 11)
Pharmacy Education     Full-text available via subscription   (Followers: 11)
Clinical Therapeutics     Hybrid Journal   (Followers: 10)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Pharmaceutical Statistics     Hybrid Journal   (Followers: 10)
Seminars in Oncology Nursing     Full-text available via subscription   (Followers: 10)
Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 10)
Toxicological Sciences     Hybrid Journal   (Followers: 10)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 10)
Biochemical Pharmacology     Hybrid Journal   (Followers: 9)
ChemMedChem     Hybrid Journal   (Followers: 9)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 9)
Drugs & Aging     Full-text available via subscription   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Medicinal Chemistry     Hybrid Journal   (Followers: 9)
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 8)
Drug Development Research     Hybrid Journal   (Followers: 8)
Epilepsy Research     Hybrid Journal   (Followers: 8)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 8)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 8)
Progress in Neuro-Psychopharmacology and Biological Psychiatry     Hybrid Journal   (Followers: 8)
Toxicology in Vitro     Hybrid Journal   (Followers: 8)
Inhalation Toxicology     Hybrid Journal   (Followers: 8)
Antiviral Research     Hybrid Journal   (Followers: 7)
Current Medicinal Chemistry     Hybrid Journal   (Followers: 7)
Drug Delivery     Open Access   (Followers: 7)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 7)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 7)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 7)
Journal of Veterinary Pharmacology and Therapeutics     Hybrid Journal   (Followers: 7)
Prescriber     Hybrid Journal   (Followers: 7)
Toxicology Mechanisms and Methods     Hybrid Journal   (Followers: 7)
Journal of Pharmaceutical Innovation     Hybrid Journal   (Followers: 7)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
Biometrical Journal     Hybrid Journal   (Followers: 6)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 6)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 6)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 6)
Human & Experimental Toxicology     Hybrid Journal   (Followers: 6)
Toxicology and Industrial Health     Hybrid Journal   (Followers: 6)
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 5)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Current Therapeutic Research     Open Access   (Followers: 5)
Reviews of Physiology, Biochemistry and Pharmacology     Hybrid Journal   (Followers: 5)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Fitoterapia     Hybrid Journal   (Followers: 5)
Journal of Pain Management & Medicine     Open Access   (Followers: 5)
Journal of Cardiovascular Pharmacology and Therapeutics     Hybrid Journal   (Followers: 5)
Journal of Separation Science     Hybrid Journal   (Followers: 5)
Scandinavian Journal of Clinical and Laboratory Investigation     Hybrid Journal   (Followers: 5)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 5)
Pharmacogenomics Journal     Hybrid Journal   (Followers: 5)
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
BioDrugs     Full-text available via subscription   (Followers: 4)
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 4)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 4)
International Journal of Pharmaceutical and Healthcare Marketing     Hybrid Journal   (Followers: 4)
Pharmaceutical Medicine     Full-text available via subscription   (Followers: 4)
Journal of Child and Adolescent Psychopharmacology     Hybrid Journal   (Followers: 4)
Journal of Infection and Chemotherapy     Hybrid Journal   (Followers: 4)
Journal of Labelled Compounds and Radiopharmaceuticals     Hybrid Journal   (Followers: 4)
Journal of Pharmacology and Experimental Therapeutics     Hybrid Journal   (Followers: 4)
Neuropharmacology     Hybrid Journal   (Followers: 4)
Planta Medica     Hybrid Journal   (Followers: 4)
Immunopharmacology and Immunotoxicology     Hybrid Journal   (Followers: 4)
Physiology International     Full-text available via subscription   (Followers: 3)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
BMC Pharmacology     Open Access   (Followers: 3)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 3)
CNS Drug Reviews     Open Access   (Followers: 3)
Current Drug Metabolism     Hybrid Journal   (Followers: 3)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
European Journal of Pharmacology     Hybrid Journal   (Followers: 3)
Frontiers in Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Human Psychopharmacology Clinical and Experimental     Hybrid Journal   (Followers: 3)
Inflammation Research     Hybrid Journal   (Followers: 3)
Investigational New Drugs     Hybrid Journal   (Followers: 3)
Journal of Aerosol Medicine and Pulmonary Drug Delivery     Hybrid Journal   (Followers: 3)
Journal of Cardiovascular Pharmacology     Hybrid Journal   (Followers: 3)
Journal of Ethnopharmacology     Hybrid Journal   (Followers: 3)
Journal of Medical Marketing     Hybrid Journal   (Followers: 3)
Journal of Pharmacological and Toxicological Methods     Hybrid Journal   (Followers: 3)
Microbial Drug Resistance     Hybrid Journal   (Followers: 3)
International Journal of Neuropsychopharmacology     Open Access   (Followers: 3)
Therapeutic Drug Monitoring     Hybrid Journal   (Followers: 3)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 3)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 2)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Current Drug Therapy     Hybrid Journal   (Followers: 2)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
Inflammopharmacology     Hybrid Journal   (Followers: 2)
Inpharma Weekly     Full-text available via subscription   (Followers: 2)
International Clinical Psychopharmacology     Hybrid Journal   (Followers: 2)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
Letters in Drug Design & Discovery     Hybrid Journal   (Followers: 2)
Medicinal Research Reviews     Hybrid Journal   (Followers: 2)
Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pharmacology Biochemistry and Behavior     Hybrid Journal   (Followers: 2)
Pharmacopsychiatry     Hybrid Journal   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Research in Social and Administrative Pharmacy     Hybrid Journal   (Followers: 2)
The Brown University Psychopharmacology Update     Hybrid Journal   (Followers: 2)
Toxicological & Environmental Chemistry     Hybrid Journal   (Followers: 2)
Toxicon     Hybrid Journal   (Followers: 2)
Journal of Microencapsulation: Microcapsules, Liposomes, Nanoparticles, Microcells, Microspheres     Hybrid Journal   (Followers: 2)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 1)
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 1)
Fundamental & Clinical Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Drug Targeting     Hybrid Journal   (Followers: 1)
Journal of Inflammation     Open Access   (Followers: 1)
Journal of Neuroimmune Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Texture Studies     Hybrid Journal   (Followers: 1)
Pharmacogenetics and Genomics     Hybrid Journal   (Followers: 1)
Particulate Science and Technology: An International Journal     Hybrid Journal   (Followers: 1)
Pharmaceutical Biology     Open Access  
Journal of Liposome Research     Hybrid Journal  
Vascular Pharmacology     Hybrid Journal  
Toxin Reviews     Hybrid Journal  
Kaohsiung Journal of Medical Sciences     Open Access  
Redox Report     Open Access  
Pharmacological Research     Hybrid Journal  
PharmacoEconomics & Outcomes News     Full-text available via subscription  
Pharmaceutical Chemistry Journal     Hybrid Journal  
NeuroMolecular Medicine     Hybrid Journal  
Journal of Ocular Pharmacology and Therapeutics     Hybrid Journal  
Harm Reduction Journal     Open Access  
Current Nanoscience     Hybrid Journal  
Infectious Disorders - Drug Targets     Hybrid Journal  
Current Bioactive Compounds     Hybrid Journal  
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Autonomic & Autacoid Pharmacology     Hybrid Journal  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

Similar Journals
Journal Cover
PharmacoEconomics
Journal Prestige (SJR): 1.998
Citation Impact (citeScore): 3
Number of Followers: 21  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1170-7690 - ISSN (Online) 1179-2027
Published by Adis Homepage  [21 journals]
  • Correction to: Understanding Clinician Preferences for Treatment
           Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and
           Urologists’ Preferences for First-Line Treatment of Locally
           Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European
           Countries

    • Free pre-print version: Loading...

      PubDate: 2024-08-01
       
  • A Systematic Review of Methods for Estimating Productivity Losses due to
           Illness or Caregiving in Low- and Middle-Income Countries

    • Free pre-print version: Loading...

      Abstract: Background Productivity losses are often included in costing studies and economic evaluations to provide a comprehensive understanding of the economic burden of disease. Global guidance on estimating productivity losses is sparse, especially for low-and middle-income countries (LMICs) where informal and unpaid work remains dominant. This study aims to describe current practices for valuing productivity losses in LMICs. Methods We performed a systematic review of studies published before April 2022 using three databases, including PubMed, Cochrane Library and Web of Science Core Collection. We included any costing or economic evaluation study conducted in a LMIC that provided methodological details on how the monetary value for productivity losses was estimated. Two reviewers independently screened articles for inclusion, extracted data and assessed the quality of the studies. Results A total of 281 articles were included. While most studies did not specify the overall approach used to measure and value productivity losses (58%), the human capital approach was the most frequently used approach to measure productivity losses when this was clearly stated (39%). The most common methods to estimate a monetary value for productivity losses were market wages (51%), self-reported wages (28%) and macroeconomic measures (15%). Conclusion Reporting standards for productivity losses in LMIC settings have room for improvement. While market wages were the most frequently used method to estimate the monetary value of productivity losses, this relies on context-specific data availability. Until a consensus is reached on if, when and how to include productivity losses in costing and economic evaluation studies, future studies could include a sensitivity analysis to explore the impact of different methods for estimating the monetary value of productivity losses.
      PubDate: 2024-08-01
       
  • Examining the Effect of Depicting a Patient Affected by a Negative
           Reimbursement Decision in Healthcare on Public Disagreement with the
           Decision

    • Free pre-print version: Loading...

      Abstract: Background The availability of increasingly advanced and expensive new health technologies puts considerable pressure on publicly financed healthcare systems. Decisions to not—or no longer—reimburse a health technology from public funding may become inevitable. Nonetheless, policymakers are often pressured to amend or revoke negative reimbursement decisions due to the public disagreement that typically follows such decisions. Public disagreement may be reinforced by the publication of pictures of individual patients in the media. Our aim was to assess the effect of depicting a patient affected by a negative reimbursement decision on public disagreement with the decision. Methods We conducted a discrete choice experiment in a representative sample of the public (n = 1008) in the Netherlands and assessed the likelihood of respondents’ disagreement with policymakers’ decision to not reimburse a new pharmaceutical for one of two patient groups. We presented a picture of one of the patients affected by the decision for one patient group and “no picture available” for the other group. The groups were described on the basis of patients’ age, health-related quality of life (HRQOL) and life expectancy (LE) before treatment, and HRQOL and LE gains from treatment. We applied random-intercept logit regression models to analyze the data. Results Our results indicate that respondents were more likely to disagree with the negative reimbursement decision when a picture of an affected patient was presented. Consistent with findings from other empirical studies, respondents were also more likely to disagree with the decision when patients were relatively young, had high levels of HRQOL and LE before treatment, and large LE gains from treatment. Conclusions This study provides evidence for the effect of depicting individual, affected patients on public disagreement with negative reimbursement decisions in healthcare. Policymakers would do well to be aware of this effect so that they can anticipate it and implement policies to mitigate associated risks.
      PubDate: 2024-08-01
       
  • Could or Should We Use Cost-Effectiveness Thresholds in the French
           Value-Based Pricing Process for New Drugs'

    • Free pre-print version: Loading...

      PubDate: 2024-08-01
       
  • Understanding Clinician Preferences for Treatment Attributes in Oncology:
           A Discrete Choice Experiment of Oncologists’ and Urologists’
           Preferences for First-Line Treatment of Locally Advanced/Unresectable
           Metastatic Urothelial Carcinoma in Five European Countries

    • Free pre-print version: Loading...

      Abstract: Introduction Prior discrete choice experiments (DCE) in oncology found that, on average, clinicians rank survival as the most important treatment attribute. We investigate heterogeneity in clinician preferences within the context of first-line treatment for advanced urothelial carcinoma in Spain, France, Italy, Germany, and the UK. Methods The online DCE included 12 treatment choice tasks, each comparing two hypothetical therapy profiles defined by treatment attributes: grade 3/4 treatment-related adverse events (TRAEs), induction and maintenance administration schedules, progression-free survival, and overall survival (OS). We used a random parameters logit model to estimate attribute relative importance (RI) (0–100%) and generate preference shares for four treatment profiles. Results were stratified by country. Preference heterogeneity was evaluated by latent class analysis. Results In August and September 2022, 498 clinicians (343 oncologists and 155 urologists) completed the DCE. OS had the strongest influence on clinicians’ preferences [RI = 62%; range, 51.6% (Germany) to 63.7% (Spain)] followed by frequency of grade 3/4 TRAEs (RI = 27%). Among treatment profiles, the chemotherapy plus immune checkpoint inhibitor maintenance therapy profile had the largest preference share [51%; range, 38% (Italy) to 56% (UK)]. Four latent classes of clinicians were identified (N = 469), with different treatment profile preferences: survival class (30.1%), trade-off class (22.4%), no strong preference class (40.9%), and aggressive treatment class (6.6%). OS was not the most important attribute for 30.0% of clinicians. Conclusion While average sample results were consistent with those of prior DCEs, this study found heterogeneity in clinician preferences within and across countries, highlighting the diversity in clinician decision making in oncology.
      PubDate: 2024-08-01
       
  • Challenges in the Assessment of a Disease Model in the NICE Single
           Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An
           External Assessment Group Perspective

    • Free pre-print version: Loading...

      PubDate: 2024-08-01
       
  • A Prototype Software Framework for Transferable Computational Health
           Economic Models and Its Early Application in Youth Mental Health

    • Free pre-print version: Loading...

      Abstract: Abstract Summary: We are developing an economic model to explore multiple topics in Australian youth mental health policy. To help make that model more readily transferable to other jurisdictions, we developed a software framework for authoring modular computational health economic models (CHEMs) (the software files that implement health economic models). We specified framework user requirements for: a simple programming syntax; a template CHEM module; tools for authoring new CHEM modules; search tools for finding existing CHEM modules; tools for supplying CHEM modules with data; reproducible analysis and reporting tools; and tools to help maintain a CHEM project website. We implemented the framework as six development version code libraries in the programming language R that integrate with online services for software development and research data archiving. We used the framework to author five development version R libraries of CHEM modules focussed on utility mapping in youth mental health. These modules provide tools for variable validation, dataset description, multi-attribute instrument scoring, construction of mapping models, reporting of mapping studies and making out of sample predictions. We assessed these CHEM module libraries as mostly meeting transparency, reusability and updatability criteria that we have previously developed, but requiring more detailed documentation and unit testing of individual modules. Our software framework has potential value as a prototype for future tools to support the development of transferable CHEMs. Code: Visit https://www.ready4-dev.com for more information about how to find, install and apply the prototype software framework.
      PubDate: 2024-08-01
       
  • A Systematic Review of Methods and Practice for Integrating Maternal,
           Fetal, and Child Health Outcomes, and Family Spillover Effects into
           Cost-Utility Analyses

    • Free pre-print version: Loading...

      Abstract: Background Maternal-perinatal interventions delivered during pregnancy or childbirth have unique characteristics that impact the health-related quality of life (HRQoL) of the mother, fetus, and newborn child. However, maternal-perinatal cost-utility analyses (CUAs) often only consider either maternal or child health outcomes. Challenges include, but are not limited to, measuring fetal, newborn, and infant health outcomes, and assessing their impact on maternal HRQoL. It is also important to recognize the impact of maternal-perinatal health on family members’ HRQoL (i.e., family spillover effects) and to incorporate these effects in maternal-perinatal CUAs. Objective The aim was to systematically review the methods used to include health outcomes of pregnant women, fetuses, and children and to incorporate family spillover effects in maternal-perinatal CUAs. Methods A literature search was conducted in Medline, Embase, EconLit, Cochrane Collection, Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Network of Agencies for Health Technology Assessment (INAHTA), and the Pediatric Economic Database Evaluation (PEDE) databases from inception to 2020 to identify maternal-perinatal CUAs that included health outcomes for pregnant women, fetuses, and/or children. The search was updated to December 2022 using PEDE. Data describing how the health outcomes of mothers, fetuses, and children were measured, incorporated, and reported along with the data on family spillover effects were extracted. Results Out of 174 maternal-perinatal CUAs identified, 62 considered the health outcomes of pregnant women, and children. Among the 54 quality-adjusted life year (QALY)-based CUAs, 12 included fetal health outcomes, the impact of fetal loss on mothers’ HRQoL, and the impact of neonatal demise on mothers’ HRQoL. Four studies considered fetal health outcomes and the effects of fetal loss on mothers’ HRQoL. One study included fetal health outcomes and the impact of neonatal demise on maternal HRQoL. Furthermore, six studies considered the impact of neonatal demise on maternal HRQoL, while four included fetal health outcomes. One study included the impact of fetal loss on maternal HRQoL. The remaining 26 only included the health outcomes of pregnant women and children. Among the eight disability-adjusted life year (DALY)-based CUAs, two measured fetal health outcomes. Out of 174 studies, only one study included family spillover effects. The most common measurement approach was to measure the health outcomes of pregnant women and children separately. Various approaches were used to assess fetal losses in terms of QALYs or DALYs and their impact on HRQoL of mothers. The most common integration approach was to sum the QALYs or DALYs for pregnant women and children. Most studies reported combined QALYs and incremental QALYs, or DALYs and incremental DALYs, at the family level for pregnant women and children. Conclusions Approximately one-third of maternal-perinatal CUAs included the health outcomes of pregnant women, fetuses, and/or children. Future CUAs of maternal-perinatal interventions, conducted from a societal perspective, should aim to incorporate health outcomes for mothers, fetuses, and children when appropriate. The various approaches used within these CUAs highlight the need for standardized measurement and integration methods, potentially leading to rigorous and standardized inclusion practices, providing higher-quality evidence to better inform decision-makers about the costs and benefits of maternal-perinatal interventions. Health Technology Assessment agencies may consider providing guidance for interventions affecting future lives in future updates.
      PubDate: 2024-08-01
       
  • Measuring the Direct Medical Costs of Hospital-Onset Infections Using an
           Analogy Costing Framework

    • Free pre-print version: Loading...

      Abstract: Background The majority of recent estimates on the direct medical cost attributable to hospital-onset infections (HOIs) has focused on device- or procedure-associated HOIs. The attributable costs of HOIs that are not associated with device use or procedures have not been extensively studied. Objective We developed simulation models of attributable cost for 16 HOIs and estimated the total direct medical cost, including nondevice-related HOIs in the USA for 2011 and 2015. Data and Methods We used total discharge costs associated with HOI-related hospitalization from the National Inpatient Sample and applied an analogy costing methodology to develop simulation models of the costs attributable to HOIs. The mean attributable cost estimate from the simulation analysis was then multiplied by previously published estimates of the number of HOIs for 2011 and 2015 to generate national estimates of direct medical costs. Results After adjusting all estimates to 2017 US dollars, attributable cost estimates for select nondevice-related infections attributable cost estimates ranged from $7661 for ear, eye, nose, throat, and mouth (EENTM) infections to $27,709 for cardiovascular system infections in 2011; and from $8394 for EENTM to $26,445 for central nervous system infections in 2016 (based on 2015 incidence data). The national direct medical costs for all HOIs were $14.6 billion in 2011 and $12.1 billion in 2016. Nondevice- and nonprocedure-associated HOIs comprise approximately 26−28% of total HOI costs. Conclusion Results suggest that nondevice- and nonprocedure-related HOIs result in considerable costs to the healthcare system.
      PubDate: 2024-07-05
       
  • Mixture and Non-mixture Cure Models for Health Technology Assessment: What
           You Need to Know

    • Free pre-print version: Loading...

      Abstract: Abstract There is increasing interest in the use of cure modelling to inform health technology assessment (HTA) due to the development of new treatments that appear to offer the potential for cure in some patients. However, cure models are often not included in evidence dossiers submitted to HTA agencies, and they are relatively rarely relied upon to inform decision-making. This is likely due to a lack of understanding of how cure models work, what they assume, and how reliable they are. In this tutorial we explain why and when cure models may be useful for HTA, describe the key characteristics of mixture and non-mixture cure models, and demonstrate their use in a range of scenarios, providing Stata code. We highlight key issues that must be taken into account by analysts when fitting these models and by reviewers and decision-makers when interpreting their predictions. In particular, we note that flexible parametric non-mixture cure models have not been used in HTA, but they offer advantages that make them well suited to an HTA context when a cure assumption is valid but follow-up is limited.
      PubDate: 2024-07-05
       
  • Evaluating the Public Health and Health Economic Impacts of Baloxavir
           Marboxil and Oseltamivir for Influenza Pandemic Control in China: A
           Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic
           Evaluation Model

    • Free pre-print version: Loading...

      Abstract: Background Pandemic influenza poses a recurring threat to public health. Antiviral drugs are vital in combating influenza pandemics. Baloxavir marboxil (BXM) is a novel agent that provides clinical and public health benefits in influenza treatment. Methods We constructed a linked dynamic transmission-economic evaluation model combining a modified susceptible–exposed–infected–recovered (SEIR) model and a decision tree model to evaluate the cost-effectiveness of adding BXM to oseltamivir in China’s influenza pandemic scenario. The cost-effectiveness was evaluated for the general population from the Chinese healthcare system perspective, although the users of BXM and oseltamivir were influenza-infected persons. The SEIR model simulated the transmission dynamics, dividing the population into four compartments: susceptible, exposed, infected, and recovered, while the decision tree model assessed disease severity and costs. We utilized data from clinical trials and observational studies in the literature to parameterize the models. Costs were based on 2021 CN¥ and not discounted due to a short time-frame of one year in the model. One-way, two-way, and probabilistic sensitivity analyses were also conducted. Results The integrated model demonstrated that adding BXM to treatment choices reduced the cumulative incidence of infection from 49.49% to 43.26% and increased quality-adjusted life years (QALYs) by 0.00021 per person compared with oseltamivir alone in the base-case scenario. The intervention also amounted to a positive net monetary benefit of CN¥77.85 per person at the willingness to pay of CN¥80,976 per QALY. Sensitivity analysis confirmed the robustness of these findings, with consistent results across varied key parameters and assumptions. Conclusions Adding BXM to treatment choices instead of only treating with oseltamivir for influenza pandemic control in China appears to be cost-effective compared with oseltamivir alone. The dual-agent strategy not only enhances population health outcomes and conserves resources, but also mitigates influenza transmission and alleviates healthcare burden.
      PubDate: 2024-07-03
       
  • Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added
           to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia

    • Free pre-print version: Loading...

      Abstract: Introduction Immunocompromised host pneumonia (ICHP) is an important cause of morbidity and mortality, yet usual care (UC) diagnostic tests often fail to identify an infectious etiology. A US-based, multicenter study (PICKUP) among ICHP patients with hematological malignancies, including hematological cell transplant recipients, showed that plasma microbial cell-free DNA (mcfDNA) sequencing provided significant additive diagnostic value. Aim The objective of this study was to perform a cost-effectiveness analysis (CEA) of adding mcfDNA sequencing to UC diagnostic testing for hospitalized ICHP patients. Methods A semi-Markov model was utilized from the US third-party payer’s perspective such that only direct costs were included, using a lifetime time horizon with discount rates of 3% for costs and benefits. Three comparators were considered: (1) All UC, which included non-invasive (NI) and invasive testing and early bronchoscopy; (2) All UC & mcfDNA; and (3) NI UC & mcfDNA & conditional UC Bronch (later bronchoscopy if the initial tests are negative). The model considered whether a probable causative infectious etiology was identified and if the patient received appropriate antimicrobial treatment through expert adjudication, and if the patient died in-hospital. The primary endpoints were total costs, life-years (LYs), equal value life-years (evLYs), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio per QALY. Extensive scenario and probabilistic sensitivity analyses (PSA) were conducted. Results At a price of $2000 (2023 USD) for the plasma mcfDNA, All UC & mcfDNA was more costly ($165,247 vs $153,642) but more effective (13.39 vs 12.47 LYs gained; 10.20 vs 9.42 evLYs gained; 10.11 vs 9.42 QALYs gained) compared to All UC alone, giving a cost/QALY of $16,761. NI UC & mcfDNA & conditional UC Bronch was also more costly ($162,655 vs $153,642) and more effective (13.19 vs 12.47 LYs gained; 9.96 vs 9.42 evLYs gained; 9.96 vs 9.42 QALYs gained) compared to All UC alone, with a cost/QALY of $16,729. The PSA showed that above a willingness-to-pay threshold of $50,000/QALY, All UC & mcfDNA was the preferred scenario on cost-effectiveness grounds (as it provides the most QALYs gained). Further scenario analyses found that All UC & mcfDNA always improved patient outcomes but was not cost saving, even when the price of mcfDNA was set to $0. Conclusions Based on the evidence available at the time of this analysis, this CEA suggests that mcfDNA may be cost-effective when added to All UC, as well as in a scenario using conditional bronchoscopy when NI testing fails to identify a probable infectious etiology for ICHP. Adding mcfDNA testing to UC diagnostic testing should allow more patients to receive appropriate therapy earlier and improve patient outcomes.
      PubDate: 2024-07-02
       
  • Estimating an EQ-5D-Y-3L Value Set for Brazil

    • Free pre-print version: Loading...

      Abstract: Introduction The EQ-5D-Y-3L is a generic measure of health-related quality of life in children and adolescents. Although the Brazilian-Portuguese EQ-5D-Y-3L version is available, there is no value set for it, hampering its use in economic evaluations. This study aimed to elicit a Brazilian EQ-5D-Y-3L value set based on preferences of the general adult population. Methods Two independent samples of adults participated in an online discrete choice experiment (DCE) survey and a composite time trade-off (cTTO) face-to-face interview. The framing was “considering your views for a 10-year-old child”. DCE data were analyzed using a mixed-logit model. The 243 DCE predicted values were mapped into the observed 28 cTTO values using linear and non-linear mapping approaches with and without intercept. Mapping approaches’ performance was assessed to estimate the most valid method to rescale DCE predicted values using the model fit (R2), Akaike Information Criteria (AIC), root mean squared error (RMSE), and mean absolute error (MAE). Results A representative sample of 1376 Brazilian adults participated (DCE, 1152; cTTO, 211). The linear mapping without intercept (R2 = 96%; AIC, − 44; RMSE, 0.0803; MAE, − 0.0479) outperformed the non-linear without intercept (R2 = 98%; AIC, − 63; RMSE, 0.1385; MAE, − 0.1320). Utilities ranged from 1 (full health) to − 0.0059 (the worst health state). Highest weights were assigned to having pain or discomfort (pain/discomfort), followed by walking about (mobility), looking after myself (self-care), doing usual activities (usual activities), and feeling worried, sad, or unhappy (anxiety/depression). Conclusion This study elicited the Brazilian EQ-5D-Y-3L value set using a mixed-logit DCE model with a power parameter based on a linear mapping without intercept, which can be used to estimate the quality-adjusted life-years for economic evaluations of health technologies targeting the Brazilian youth population.
      PubDate: 2024-07-02
       
  • The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers,
           Estimation Methods, and Approaches to Value Recognition in Health
           Technology Assessment

    • Free pre-print version: Loading...

      Abstract: Abstract Expanding flexible vaccine manufacturing capacity (FVMC) for routine vaccines could facilitate more timely access to novel vaccines during future pandemics. Vaccine manufacturing capacity is ‘flexible’ if it is built on a technology platform that allows rapid adaption to new infectious agents. The added value of routine vaccines produced using a flexible platform for pandemic preparedness is not currently recognised in conventional health technology assessment (HTA) methods. We start by examining the current state of play of incentives for FVMC and exploring the relation between flexible and spare capacity. We then establish the key factors for estimating FVMC and draw from established frameworks to identify relevant value drivers. The role of FVMC as a countermeasure against pandemic risks is deemed an additional value attribute that should be recognised. Next, we address the gap in the vaccine-valuation literature between the conceptual understanding of the value of additional FVMC and the availability of accurate and reliable tools for its estimation to facilitate integration into HTA. Three practical approaches for estimating the value of additional FVMC are discussed: stated and revealed preference studies, macroeconomic modelling, and benefit–cost analysis. Lastly, we review how value recognition of additional FVMC can be realised within the HTA process for routine vaccines manufactured on flexible platforms. We argue that, while the value of additional FVMC is uncertain and further research is needed to help to better estimate it, the value of increased pandemic preparedness is likely to be too large to be ignored.
      PubDate: 2024-07-01
       
  • Barriers and Facilitators of Using R for Decision Analytic Modeling in
           Health Technology Assessment: Focus Group Results

    • Free pre-print version: Loading...

      Abstract: Background and Objective Decision models for health technology assessment (HTA) are largely submitted to HTA agencies using commercial software, which has known limitations. The use of the open-source programming language R has been suggested because of its efficiency, transparency, reproducibility, and ability to consider complex analyses. However, its use in HTA remains limited. This qualitative study aimed to explore the main reasons for this slow uptake of R in HTA and identify tangible facilitators. Methods We undertook two semi-structured focus group discussions with 24 key stakeholders from government agencies, consultancy, pharmaceutical companies, and academia. Two 1.5-hour discussions reflected on barriers identified in a previous study and highlighted additional barriers. Discussions were recorded and semi-transcribed, and data were organized and summarized into key themes. Results Human resources constraints were identified as a key barrier, including a lack of training, prioritization and collaboration, and resistance to change. Another key barrier was the lack of acceptance, or clear guidance, around submissions in R by HTA agencies. Participants also highlighted a lack of communication around accepted packages and decision model structures, and between HTA agencies on standard decision modeling structures. Conclusions There is a need for standardization, which can facilitate decision model sharing, coding homogeneity, and improved country adaptations. The creation of training materials and tailored workshops was identified as a key short-term facilitator. Increased communication and engagement of stakeholders could also facilitate the use of R by identifying needs and opportunities, encouraging HTA agencies to address structural barriers, and increasing incentives to use R.
      PubDate: 2024-07-01
       
  • Quality Appraisal in Systematic Literature Reviews of Studies Eliciting
           Health State Utility Values: Conceptual Considerations

    • Free pre-print version: Loading...

      Abstract: Background The increasing number of studies that generate health state utility values (HSUVs) and the impact of HSUVs on cost-utility analyses make a robust tailored quality appraisal (QA) tool for systematic reviews of these studies necessary. Objective This study aimed to address conceptual issues regarding QA in systematic reviews of studies eliciting HSUVs by establishing a consensus on the definitions, dimensions and scope of a QA tool specific to this context. Methods A modified Delphi method was used in this study. An international multidisciplinary panel of seven experts was purposively assembled. The experts engaged in two anonymous online survey rounds. After each round, the experts received structured and controlled feedback on the previous phase. Controlled feedback allowed the experts to re-evaluate and adjust their positions based on collective insights. Following these surveys, a virtual face-to-face meeting was held to resolve outstanding issues. Consensus was defined a priori at all stages of the modified Delphi process. Results The response rates to the first-round and second-round questionnaires and the virtual consensus meeting were 100%, 86% and 71%, respectively. The entire process culminated in a consensus on the definitions of scientific quality, QA, the three QA dimensions—reporting, relevance and  methodological quality—and the scope of a QA tool specific to studies that elicit HSUVs. Conclusions Achieving this consensus marks a pivotal step towards developing a QA tool specific to systematic reviews of studies eliciting HSUVs. Future research will build on this foundation, identify QA items, signalling questions and response options, and develop a QA tool specific to studies eliciting HSUVs.
      PubDate: 2024-07-01
       
  • Cost-of-Illness of Skin Cancer: A Systematic Review

    • Free pre-print version: Loading...

      Abstract: Background Skin cancer’s rising incidence demands understanding of its economic impact. The current understanding is fragmented because of the various methodological approaches applied in skin cancer cost-of-illness studies. Objective This study systematically reviews melanoma and keratinocyte carcinoma cost-of-illness studies to provide an overview of the applied methodological approaches and to identify the main cost drivers. Methods This systematic review was conducted adhering to the 2020 PRISMA guidelines. PubMed, Embase, and Web of Science were searched from December 2022 until December 2023 using a search strategy with entry terms related to the concepts of skin cancer and cost of illness. The records were screened on the basis of the title and abstract and subsequently on full text against predetermined eligibility criteria. Articles published before 2012 were excluded. A nine-item checklist adapted for cost-of-illness studies was used to assess the methodological quality of the articles. Results This review included a total of 45 studies, together evaluating more than half a million patients. The majority of the studies (n = 36) focused on melanoma skin cancer, a few (n = 3) focused on keratinocyte carcinomas, and 6 studies examined both. Direct costs were estimated in all studies, while indirect costs were only estimated in nine studies. Considerable heterogeneity was observed across studies, mainly owing to disparities in study population, methodological approaches, included cost categories, and differences in healthcare systems. In melanoma skin cancer, both direct and indirect costs increased with progressing tumor stage. In advanced stage melanoma, systemic therapy emerged as the main cost driver. In contrast, for keratinocyte carcinoma no obvious cost drivers were identified. Conclusions A homogeneous skin cancer cost-of-illness study design would be beneficial to enhance between-studies comparability, identification of cost drivers, and support evidence-based decision-making for skin cancer.
      PubDate: 2024-07-01
       
  • Advances in Addressing Patient Heterogeneity in Economic Evaluation: A
           Review of the Methods Literature

    • Free pre-print version: Loading...

      Abstract: Abstract Cost-effectiveness analyses commonly use population or sample averages, which can mask key differences across subgroups and may lead to suboptimal resource allocation. Despite there being several new methods developed over the last decade, there is no recent summary of what methods are available to researchers. This review sought to identify advances in methods for addressing patient heterogeneity in economic evaluations and to provide an overview of these methods. A literature search was conducted using the Econlit, Embase and MEDLINE databases to identify studies published after 2011 (date of a previous review on this topic). Eligible studies needed to have an explicit methodological focus, related to how patient heterogeneity can be accounted for within a full economic evaluation. Sixteen studies were included in the review. Methodologies were varied and included regression techniques, model design and value of information analysis. Recent publications have applied methodologies more commonly used in other fields, such as machine learning and causal forests. Commonly noted challenges associated with considering patient heterogeneity included data availability (e.g., sample size), statistical issues (e.g., risk of false positives) and practical factors (e.g., computation time). A range of methods are available to address patient heterogeneity in economic evaluation, with relevant methods differing according to research question, scope of the economic evaluation and data availability. Researchers need to be aware of the challenges associated with addressing patient heterogeneity (e.g., data availability) to ensure findings are meaningful and robust. Future research is needed to assess whether and how methods are being applied in practice.
      PubDate: 2024-07-01
       
  • Advancing Methods to Measure and Reward Healthcare Innovation

    • Free pre-print version: Loading...

      PubDate: 2024-06-24
       
  • PharmacoEconomics Supplement

    • Free pre-print version: Loading...

      PubDate: 2024-06-15
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.92.91.54
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-
JournalTOCs
 
 

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted by number of followers
Nature Reviews Drug Discovery     Full-text available via subscription   (Followers: 352)
Journal of Clinical Oncology     Hybrid Journal   (Followers: 260)
International Journal of Drug Policy     Hybrid Journal   (Followers: 241)
Journal of Medicinal Chemistry     Hybrid Journal   (Followers: 167)
Drugs     Full-text available via subscription   (Followers: 146)
Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 140)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 95)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 84)
Drug Safety     Full-text available via subscription   (Followers: 81)
Pharmaceutical Research     Hybrid Journal   (Followers: 69)
Drug Discovery Today     Full-text available via subscription   (Followers: 63)
Biomaterials     Hybrid Journal   (Followers: 54)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 52)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 31)
Pharmacoepidemiology and Drug Safety     Hybrid Journal   (Followers: 29)
AAPS Journal     Hybrid Journal   (Followers: 29)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 27)
Journal of Pain & Palliative Care Pharmacotherapy     Hybrid Journal   (Followers: 26)
Regulatory Toxicology and Pharmacology     Hybrid Journal   (Followers: 26)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 25)
Journal of Controlled Release     Hybrid Journal   (Followers: 25)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 25)
International Journal of Pharmacy Practice     Full-text available via subscription   (Followers: 24)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 23)
International Journal of Pharmaceutics     Hybrid Journal   (Followers: 23)
Journal of Clinical Psychopharmacology     Hybrid Journal   (Followers: 23)
Journal of Pharmacy and Pharmacology     Full-text available via subscription   (Followers: 23)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 22)
PharmacoEconomics     Full-text available via subscription   (Followers: 21)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 20)
Chemical Research in Toxicology     Hybrid Journal   (Followers: 20)
Trends in Pharmacological Sciences     Full-text available via subscription   (Followers: 17)
Clinical Toxicology     Hybrid Journal   (Followers: 17)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 16)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Journal of Natural Products     Hybrid Journal   (Followers: 16)
Journal of Pharmacokinetics and Pharmacodynamics     Hybrid Journal   (Followers: 16)
Toxicology and Applied Pharmacology     Hybrid Journal   (Followers: 16)
Pharmaceutical Development and Technology     Hybrid Journal   (Followers: 16)
Journal of Applied Toxicology     Hybrid Journal   (Followers: 15)
Psychopharmacology     Hybrid Journal   (Followers: 15)
Journal of Clinical Pharmacy and Therapeutics     Hybrid Journal   (Followers: 14)
Journal of Oncology Pharmacy Practice     Hybrid Journal   (Followers: 14)
Journal of the American Pharmacists Association     Full-text available via subscription   (Followers: 14)
Toxicology     Hybrid Journal   (Followers: 14)
International Journal of Toxicology     Hybrid Journal   (Followers: 13)
Journal of Pharmaceutical and Biomedical Analysis     Hybrid Journal   (Followers: 13)
Journal of Pharmacy Practice     Hybrid Journal   (Followers: 13)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 12)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 12)
Clinical Trials     Hybrid Journal   (Followers: 12)
Toxicology Letters     Hybrid Journal   (Followers: 12)
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 12)
American Journal of Therapeutics     Hybrid Journal   (Followers: 11)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 11)
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 11)
Journal of Psychopharmacology     Hybrid Journal   (Followers: 11)
Pharmacy Education     Full-text available via subscription   (Followers: 11)
Clinical Therapeutics     Hybrid Journal   (Followers: 10)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Pharmaceutical Statistics     Hybrid Journal   (Followers: 10)
Seminars in Oncology Nursing     Full-text available via subscription   (Followers: 10)
Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 10)
Toxicological Sciences     Hybrid Journal   (Followers: 10)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 10)
Biochemical Pharmacology     Hybrid Journal   (Followers: 9)
ChemMedChem     Hybrid Journal   (Followers: 9)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 9)
Drugs & Aging     Full-text available via subscription   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Medicinal Chemistry     Hybrid Journal   (Followers: 9)
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 8)
Drug Development Research     Hybrid Journal   (Followers: 8)
Epilepsy Research     Hybrid Journal   (Followers: 8)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 8)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 8)
Progress in Neuro-Psychopharmacology and Biological Psychiatry     Hybrid Journal   (Followers: 8)
Toxicology in Vitro     Hybrid Journal   (Followers: 8)
Inhalation Toxicology     Hybrid Journal   (Followers: 8)
Antiviral Research     Hybrid Journal   (Followers: 7)
Current Medicinal Chemistry     Hybrid Journal   (Followers: 7)
Drug Delivery     Open Access   (Followers: 7)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 7)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 7)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 7)
Journal of Veterinary Pharmacology and Therapeutics     Hybrid Journal   (Followers: 7)
Prescriber     Hybrid Journal   (Followers: 7)
Toxicology Mechanisms and Methods     Hybrid Journal   (Followers: 7)
Journal of Pharmaceutical Innovation     Hybrid Journal   (Followers: 7)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
Biometrical Journal     Hybrid Journal   (Followers: 6)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 6)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 6)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 6)
Human & Experimental Toxicology     Hybrid Journal   (Followers: 6)
Toxicology and Industrial Health     Hybrid Journal   (Followers: 6)
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 5)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Current Therapeutic Research     Open Access   (Followers: 5)
Reviews of Physiology, Biochemistry and Pharmacology     Hybrid Journal   (Followers: 5)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Fitoterapia     Hybrid Journal   (Followers: 5)
Journal of Pain Management & Medicine     Open Access   (Followers: 5)
Journal of Cardiovascular Pharmacology and Therapeutics     Hybrid Journal   (Followers: 5)
Journal of Separation Science     Hybrid Journal   (Followers: 5)
Scandinavian Journal of Clinical and Laboratory Investigation     Hybrid Journal   (Followers: 5)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 5)
Pharmacogenomics Journal     Hybrid Journal   (Followers: 5)
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
BioDrugs     Full-text available via subscription   (Followers: 4)
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 4)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 4)
International Journal of Pharmaceutical and Healthcare Marketing     Hybrid Journal   (Followers: 4)
Pharmaceutical Medicine     Full-text available via subscription   (Followers: 4)
Journal of Child and Adolescent Psychopharmacology     Hybrid Journal   (Followers: 4)
Journal of Infection and Chemotherapy     Hybrid Journal   (Followers: 4)
Journal of Labelled Compounds and Radiopharmaceuticals     Hybrid Journal   (Followers: 4)
Journal of Pharmacology and Experimental Therapeutics     Hybrid Journal   (Followers: 4)
Neuropharmacology     Hybrid Journal   (Followers: 4)
Planta Medica     Hybrid Journal   (Followers: 4)
Immunopharmacology and Immunotoxicology     Hybrid Journal   (Followers: 4)
Physiology International     Full-text available via subscription   (Followers: 3)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
BMC Pharmacology     Open Access   (Followers: 3)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 3)
CNS Drug Reviews     Open Access   (Followers: 3)
Current Drug Metabolism     Hybrid Journal   (Followers: 3)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
European Journal of Pharmacology     Hybrid Journal   (Followers: 3)
Frontiers in Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Human Psychopharmacology Clinical and Experimental     Hybrid Journal   (Followers: 3)
Inflammation Research     Hybrid Journal   (Followers: 3)
Investigational New Drugs     Hybrid Journal   (Followers: 3)
Journal of Aerosol Medicine and Pulmonary Drug Delivery     Hybrid Journal   (Followers: 3)
Journal of Cardiovascular Pharmacology     Hybrid Journal   (Followers: 3)
Journal of Ethnopharmacology     Hybrid Journal   (Followers: 3)
Journal of Medical Marketing     Hybrid Journal   (Followers: 3)
Journal of Pharmacological and Toxicological Methods     Hybrid Journal   (Followers: 3)
Microbial Drug Resistance     Hybrid Journal   (Followers: 3)
International Journal of Neuropsychopharmacology     Open Access   (Followers: 3)
Therapeutic Drug Monitoring     Hybrid Journal   (Followers: 3)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 3)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 2)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Current Drug Therapy     Hybrid Journal   (Followers: 2)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
Inflammopharmacology     Hybrid Journal   (Followers: 2)
Inpharma Weekly     Full-text available via subscription   (Followers: 2)
International Clinical Psychopharmacology     Hybrid Journal   (Followers: 2)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
Letters in Drug Design & Discovery     Hybrid Journal   (Followers: 2)
Medicinal Research Reviews     Hybrid Journal   (Followers: 2)
Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pharmacology Biochemistry and Behavior     Hybrid Journal   (Followers: 2)
Pharmacopsychiatry     Hybrid Journal   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Research in Social and Administrative Pharmacy     Hybrid Journal   (Followers: 2)
The Brown University Psychopharmacology Update     Hybrid Journal   (Followers: 2)
Toxicological & Environmental Chemistry     Hybrid Journal   (Followers: 2)
Toxicon     Hybrid Journal   (Followers: 2)
Journal of Microencapsulation: Microcapsules, Liposomes, Nanoparticles, Microcells, Microspheres     Hybrid Journal   (Followers: 2)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 1)
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 1)
Fundamental & Clinical Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Drug Targeting     Hybrid Journal   (Followers: 1)
Journal of Inflammation     Open Access   (Followers: 1)
Journal of Neuroimmune Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Texture Studies     Hybrid Journal   (Followers: 1)
Pharmacogenetics and Genomics     Hybrid Journal   (Followers: 1)
Particulate Science and Technology: An International Journal     Hybrid Journal   (Followers: 1)
Pharmaceutical Biology     Open Access  
Journal of Liposome Research     Hybrid Journal  
Vascular Pharmacology     Hybrid Journal  
Toxin Reviews     Hybrid Journal  
Kaohsiung Journal of Medical Sciences     Open Access  
Redox Report     Open Access  
Pharmacological Research     Hybrid Journal  
PharmacoEconomics & Outcomes News     Full-text available via subscription  
Pharmaceutical Chemistry Journal     Hybrid Journal  
NeuroMolecular Medicine     Hybrid Journal  
Journal of Ocular Pharmacology and Therapeutics     Hybrid Journal  
Harm Reduction Journal     Open Access  
Current Nanoscience     Hybrid Journal  
Infectious Disorders - Drug Targets     Hybrid Journal  
Current Bioactive Compounds     Hybrid Journal  
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Autonomic & Autacoid Pharmacology     Hybrid Journal  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

Similar Journals
Similar Journals
HOME > Browse the 73 Subjects covered by JournalTOCs  
SubjectTotal Journals
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.92.91.54
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-